Aditi Singh

Dr. Aditi Singh

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ASAditi Singh
Aditi Singh
ESElaine Shum
Elaine Shum
LRLakshmi Rajdev
Lakshmi Rajdev
HCHaiying Cheng
Haiying Cheng
SGSANJAY GOEL
SANJAY GOEL
Balazs HalmosBalazs Halmos
Balazs Halmos
Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the community remains unknown. Methods: we conducted a retrospective study of all patients that underwent CGP as part of routine cancer management from January 2013 to June 2017 at an academic community-based NCI-designated cancer center. CGP was done in addition to established first tier reflex molecular testing as per national guidelines (e.g., EGFR/ALK for non-small cell lung cancer (NSCLC) and extended-RAS for colorectal cancer). Results: 349 tests were sent for CGP from 333 patients and 95% had at least one actionable genomic alteration reported. According to the reported results, 23.2% had a Food and Drug Administration (FDA) approved therapy available, 61.3% had an off-label therapy available and 77.9% were potentially eligible for a clinical trial. Treatment recommendations were also reviewed within the OncoKB database and 47% of them were not clinically validated therapies. The CGP results led to treatment change in only 35 patients (10%), most commonly in NSCLC. Nineteen of these patients (54% of those treated and 5% of total) had documented clinical benefit with targeted therapy. Conclusion: we demonstrate that routine use of CGP in the community across all cancer types detects potentially actionable genomic alterations in a majority of patients, however has modest clinical impact enriched in the NSCLC subset.

1 January 2021 in Clinical Lung Cancer
Verified
Journal Article
Closed access
LSLova Sun
Lova Sun
CDChristiana W. Davis
Christiana W. Davis
WHWei-Ting Hwang
Wei-Ting Hwang
SJSeth Jeffries
Seth Jeffries
LSLydia Frenzel Sulyok
Lydia Frenzel Sulyok
CACharu Aggarwal
Charu Aggarwal

18 December 2017 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
ASAditi Singh
Aditi Singh
DHDiego Adrianzen Herrera
Diego Adrianzen Herrera
YZYifei Zhang
Yifei Zhang
RPRoman Perez-Soler
Roman Perez-Soler
HCHaiying Cheng
Haiying Cheng
Introduction: Squamous cell lung cancer (SQCLC) is the second most common subtype of non-small cell lung cancer (NSCLC) and has limited therapeutic options. Its development is likely a result of a multistep process in response to chronic tobacco exposure, involving sequential metaplasia, dysplasia and invasive carcinoma. Its complex genomic landscape has recently been revealed but no driver mutations have been validated that could lead to molecularly targeted therapy as have emerged in lung adenocarcinoma. Few preclinical murine models exist for testing and developing novel therapeutics in SQCLC. Areas covered: This review discusses the pathophysiology and molecular underpinnings of SQCLC that have limited the development of animal models. It then explores the advantages and limitations of a variety of existing mouse models and illustrates their potential application in drug discovery and chemoprevention. Expert opinion: There are several challenges in the development of mouse models for SQCLC, such as lack of validated driver genetic alterations, unclear cell of origin, and difficulty in reproducing the sophisticated tumor microenvironment of human disease. Nevertheless, several successful SQCLC murine models have emerged, especially Patient Derived Xenografts (PDXs) and Genetically Engineered Mouse Models (GEMMs). Continued efforts are needed to generate more SQCLC animal models to better understand its carcinogenesis and metastasis and to further test novel therapeutic strategies.

10 August 2024 in Lung Cancer
Verified
Journal Article
Closed access
ABAdam A. Barsouk
Adam A. Barsouk
OEOmar Elghawy
Omar Elghawy
AHAlec Heidlauf
Alec Heidlauf
CYConnie Yu
Connie Yu
LWLucy Wang
Lucy Wang
CLCorey Langer
Corey Langer

1 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CDChristopher Davella
Christopher Davella
EBErin Mary Bange
Erin Mary Bange
ASAditi Singh
Aditi Singh
DDDavid W. Dougherty
David W. Dougherty
PGPeter Edward Gabriel
Peter Edward Gabriel
LSLawrence N. Shulman
Lawrence N. Shulman